Lifestream and Polymer resolve patent wrangle:
This article was originally published in Clinica
Lifestream Technologies has reached a settlement in its patent infringement lawsuit filed against Polymer Technology Systems, a private developer of rapid cholesterol tests. In the agreement, Polymer is to make royalty payments to Lifestream for future sales of products incorporating the latter's HDL (high density lipoprotein) technology, the subject of the dispute. The resolution follows shortly after Lifestream won its appeal to have overturned an initial ruling that found Polymer not guilty of infringement.
You may also be interested in...
As generalist investors continue to push higher the stock prices of biotech companies that announce the most tenuous of coronavirus developments, the track record of biotech companies developing even vaccines for which the antigen is proven to be safe and efficacious remains poor.
In a bipartisan move, the US Senate is moving to impose new rules on companies - including those from China - seeking US initial public offerings, adding further uncertainty over such plans and further stoking trade tensions.
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.